Alector Announces Appointment of Marc Grasso, M.D., as Chief Financial Officer
08 February 2022 - 12:30AM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering the discovery and development of
immuno-neurology therapeutics, today announced the appointment of
Marc Grasso, M.D., as Chief Financial Officer (CFO). Dr. Grasso
brings extensive biotechnology industry leadership experience,
including a successful track record in finance, corporate
development and strategic leadership. As Alector’s CFO, Dr. Grasso
will lead all aspects of the company’s financial operations and
play a critical role in supporting corporate strategy. Dr. Grasso
will report to Arnon Rosenthal, Ph.D., Chief Executive Officer of
Alector.
“I’m pleased to welcome Marc as the newest member of our
leadership team,” said Dr. Rosenthal. “Marc brings considerable
experience in corporate finance and a deep knowledge of our
industry. His financial and corporate strategy capabilities and
medical background will be invaluable as we continue to advance our
clinical pipeline toward late-stage studies and bring new
immuno-neurology and immuno-oncology candidates into the
clinic.”
"Alector's strong capital position, world-class partnerships and
leading immuno-neurology pipeline make now a very compelling time
to join," said Dr. Grasso. "I am thrilled to have the opportunity
to work with this experienced team and look forward to contributing
to Alector's mission to develop therapies that restore healthy
function to the brain."
Dr. Grasso succeeds Linda Rubinstein, Partner at FLG Partners,
who served as interim CFO with Alector since September 2021. Dr.
Rosenthal added, “On behalf of Alector’s team, I would like to
express our appreciation for Linda’s contributions during the past
several months.”
Dr. Grasso joins Alector from Kura Oncology, Inc., where he
served as Chief Financial Officer and Chief Business Officer. Prior
to Kura Oncology, he served as Managing Director of Stifel, where
he was responsible for building and managing the west coast life
sciences and biotechnology investment banking business. Previously,
Dr. Grasso was Managing Director of Investment Banking in the
Global Healthcare Group at UBS, focused on the biotechnology
sector, and prior to that, he was Managing Director of Investment
Banking at Leerink Swann, where he was instrumental in the west
coast expansion of their franchise. Dr. Grasso joined Leerink from
Morgan Stanley and earlier held positions in the Global Healthcare
Group of Credit Suisse First Boston and at Deutsche Banc Alex.
Brown. Dr. Grasso received his M.D. from the Johns Hopkins
University School of Medicine, where he also performed research in
molecular oncology. He obtained an A.B. in molecular biology with
honors from Princeton University.
About AlectorAlector is a clinical-stage
biotechnology company pioneering immuno-neurology, a novel
therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a root
cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable the rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and target
genetically defined patient populations in frontotemporal dementia,
Alzheimer’s disease and amyloid lateral sclerosis (ALS). This
scientific approach is also the basis for the company’s
immuno-oncology programs. Alector is headquartered in South San
Francisco, California. For additional information, please visit
www.alector.com.
Alector ContactsMichelle CorralVP,
Communications and Investor
Relations650-808-7016michelle.corral@alector.com
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Eric Kasper/Carrie McKimArgot
Partners212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Apr 2023 to Apr 2024